Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Published on by Cell Biologist

Dr. Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Great Ormond Street Hospital | United Kingdom

Kimberly Coughlan Gilmour is a leading expert in immunology, molecular diagnostics, and cell-based therapeutic development. Her early academic work contributed foundational insights into cytokine signaling, particularly the regulation of the Interferon Regulatory Factor-1 (IRF-1) gene and the signal transduction pathways activated by prolactin and interleukin-2. During her postdoctoral research, she investigated mechanisms governing thymocyte proliferation and differentiation using retroviral manipulation of murine thymic organ cultures, advancing understanding of T-cell development.

Gilmour has played a pivotal role in the evolution of clinical immunology diagnostics, leading the development of national services for the molecular diagnosis of primary immunodeficiency disorders. She has been instrumental in translating complex research methodologies—including gene expression analysis, retroviral and lentiviral transduction, and thymus tissue culture—into routine clinical tools that directly inform patient management. Her work supports post-treatment monitoring for haematopoietic stem cell transplantation, gene therapy, and targeted antibody-based interventions.

As a leader in cell therapy, she has overseen the implementation of advanced cellular manufacturing processes and supervised the clinical authorization of personalized therapeutic products. Her career integrates immunogenetics, translational science, and cellular therapy innovation, significantly shaping clinical practice for paediatric patients with rare and complex immune disorders.

Profiles: Scopus | Orcid

Featured Publications:

  • Maimaris, J., Roa-Bautista, A., Sohail, M., et al. (2025). Griscelli Syndrome Type 2: Comprehensive analysis of 149 new and previously described patients with RAB27A deficiency. Journal of Clinical Immunology, 45(50).

  • Author(s) Unknown. (2025). Safety and diagnostic utility of brain biopsy and metagenomics in decision-making for patients with inborn errors of immunity (IEI) and unexplained neurological manifestations. Journal of Clinical Immunology, 45, 86.

  • Booth, C., Masiuk, K., Vazouras, K., Fernandes, A., Xu-Bayford, J., Campo Fernandez, B., Roy, S., Curio-Penny, B., Arnold, J., Terrazas, D., Reid, J., Gilmour, K. C., Adams, S., Mediavilla, E. A., Mhaldien, L., O’Toole, G., Ahmed, R., Garabedian, E., Malech, H., De Ravin, S. S., Moore, T. B., De Oliveira, S., Pellin, D., Lin, T.-Y., Dang, T. T., Cornetta, K., Hershfield, M. S., Hara, H., Thrasher, A. J., Gaspar, H. B., & Kohn, D. B. (2025). Long-term safety and efficacy of gene therapy for adenosine deaminase deficiency. New England Journal of Medicine, 393(15), 1486–1497.

  • Guardo, D., Mishra, A. K., Rashed, H., Gilmour, K. C., Adams, S., Pinner, D., Sauer, M., Vora, A., Veys, P., Pavasovic, V., Rao, K., & Qasim, W. (2025). Long-term outcomes of genome-edited “universal” CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center. Blood Advances, 9(18), 4750–4754.

 

Borros Arneth | Pathobiochemistry | Outstanding Scientist Award

Published on by Cell Biologist

Dr. Borros Arneth | Pathobiochemistry | Outstanding Scientist Award

Justus Liebig University Giessen and Philipps University Marburg Germany | Germany

Dr. Borros Michael Arneth is a medical researcher specializing in clinical chemistry, laboratory medicine, molecular diagnostics, and pathobiochemistry. His academic foundation was established at the Johann Wolfgang Goethe University in Frankfurt am Main, where he studied biochemistry and human medicine. His doctoral research focused on magnetic resonance spectroscopic investigations of fatty acid-binding proteins (FABP) in HIV patients, contributing to the understanding of biochemical alterations in neurodegenerative and infectious diseases. Over his career, Dr. Arneth has served as a research assistant and later as a senior physician at leading institutions, including the Carl Gustav Carus University Hospital in Dresden and the University Hospital Mainz. His expertise extends to areas such as clinical biochemistry, immunology, and medical microbiology. He has achieved recognition as a European Specialist in Clinical Chemistry and Laboratory Medicine (EurClinChem) and has been actively involved in scientific publishing as an editor and reviewer for multiple international journals, including Clinical Biochemistry and the International Journal of Immunology. His research emphasizes biochemical mechanisms underlying disease processes, molecular diagnostics, and advancements in laboratory medicine for clinical applications.

Profiles: Google Scholar | Orcid

Featured Publications:

Arneth, B., Arneth, R., & Shams, M. (2019). Metabolomics of type 1 and type 2 diabetes. International Journal of Molecular Sciences, 20(10), 2467.

Shams, M. E. E., Arneth, B., Hiemke, C., Dragicevic, A., Müller, M. J., Kaiser, R., & others. (2006). CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Journal of Clinical Pharmacy and Therapeutics, 31(5), 493–502.

Arneth, B. (2018). Update on the types and usage of liquid biopsies in the clinical setting: A systematic review. BMC Cancer, 18(1), 527.

Arneth, B. M. (2019). Impact of B cells to the pathophysiology of multiple sclerosis. Journal of Neuroinflammation, 16(1), 128.

Marco Leitzke | immunology | Best Researcher Award

Published on by Cell Biologist

Dr. Marco Leitzke | immunology | Best Researcher Award

Dr. Marco Leitzke, Helios clinics, Germany

Dr. Marco Leitzke, born in 1970 in Karl-Marx-Stadt, Germany, is a senior anesthesiologist and pioneering researcher in neuromodulation and post-viral syndromes. He has served as Senior Consultant in Anesthesiology and Intensive Care at Helios Clinic Leisnig since 2015 and has extensive experience in pain therapy and palliative medicine. Renowned for his innovative studies on autonomic dysfunction, Dr. Leitzke has published extensively on cholinergic neurotransmission, COVID-19 coagulopathy, and vagus nerve stimulation. His recent focus on Long COVID as a disorder of disrupted acetylcholine signaling has gained significant scientific attention. With a dual career in clinical practice and experimental research, he bridges the gap between bedside and bench. His work earned him accolades, including a Poster Award at the 1st Long COVID Congress in Jena. Passionate about translational medicine, Dr. Leitzke continues to drive forward the understanding and treatment of complex neuroimmune disorders.

Publication Profile: 

Google Scholar

Scopus

Education:

Dr. Leitzke’s medical education and specialization reflect a deep commitment to anesthesiology and neurobiological research. He became a board-certified specialist in anesthesiology in 2006 and has built on this foundation with focused training in advanced pain management, ultrasound-guided interventions, and emergency medicine. He undertook specialized pain therapy training in 2015 and interventional pain techniques in 2014. In 2019, he began training as an Antibiotic Stewardship (ABS) expert physician, further demonstrating his holistic approach to patient safety and infection control. He also completed a transthoracic echocardiography course in 2018, showcasing his commitment to continuous learning and cross-disciplinary skills. This diverse academic background provides the basis for his translational research into neuroimmune and autonomic disorders, with a strong emphasis on clinical application. His combination of anesthesiology, ultrasound, pain therapy, and experimental neurobiology positions him as a uniquely skilled researcher bridging clinical practice and neuroscience.

Experience:

Dr. Marco Leitzke brings over two decades of clinical experience, predominantly in anesthesiology, intensive care, pain therapy, and palliative medicine. Since 2015, he has held the position of Senior Consultant at the Helios Clinic in Leisnig, where he leads interdisciplinary efforts in patient care and clinical innovation. Prior to this, he served as Senior Consultant at Asklepios Clinic Weißenfels from 2011 to 2014, while also operating as a freelance physician in Zeitz. His professional focus spans acute and chronic pain, complex anesthesia procedures, and critical care management, underpinned by a solid emergency medicine foundation gained since 2001. His hands-on experience with ultrasound-guided interventions, vagal modulation therapies, and autonomic diagnostics directly informs his research into the pathophysiology of post-viral syndromes. The integration of clinical insight and scientific exploration marks him as a dual-domain expert, fostering new therapeutic approaches rooted in both laboratory evidence and patient outcomes.

Research Focus:

Dr. Leitzke’s research centers on cholinergic neurotransmission and its impairment in acute and chronic post-viral conditions, particularly Long COVID. His central hypothesis suggests that autonomic dysfunction and neuromodulatory imbalance—specifically, disruption of the vagus nerve and acetylcholine pathways—underlie many post-viral symptoms. Through translational models using animal studies and human imaging, he explores therapeutic modulation, including vagal nerve stimulation and nicotine administration, to restore autonomic balance. His research extends to the role of NF-κB activation in COVID-19-associated coagulopathy, suggesting molecular pathways that link inflammation, clotting, and neuroimmune dysfunction. A hallmark of his work is the use of advanced imaging techniques (e.g., PET scans) to quantify cerebral receptor activity, particularly α7 nicotinic acetylcholine receptors. This integrative and experimental approach offers new perspectives on diagnostics and treatment in neuroimmune conditions, making his work highly relevant to both the scientific and medical communities in the era of post-COVID syndromes.

Publications Top Notes:

  1. 📖 Long COVID – A Critical Disruption of Cholinergic Neurotransmission? (Springer Nature, 2025)

  2. 📖 Is the Post-COVID-19 Syndrome a Severe Impairment of Acetylcholine-Orchestrated Neuromodulation That Responds to Nicotine Administration? (Springer Nature, 2023)

  3. 🏅 COVID-19 – The Ultimate NF-κB Rush and the Crucial Importance of Nicotinic Acetylcholine Receptors (Poster Award, Long COVID Congress, 2022)

  4. 🔬 Experimental Design for PET Detection of α7nAChR Under Gastric Vagus Nerve Stimulation in Piglets (DAS PLUS AN SCHUTZ, 2022)

  5. 🧠 The Viral Accelerated NF-κB Pathway and COVID-19-Associated Coagulopathy – A Case Report (Fortune Journals, 2021)

  6. 🧪 Afferent Vagal Stimulation via Gastric Electrical Stimulation Alters Sympathetic-Vagal Balance in Pigs – A Pilot Trial (Journal of Biological Regulators, 2021)

  7. ⚖️ Autonomic Balance Determines the Severity of COVID-19 Courses (Springer Nature, 2020)

  8. 🧮 A Semi-Automated Algorithm for Hypothalamus Volumetry in 3 Tesla MRI (Psychiatry Research: Neuroimaging, 2018)

  9. 🧬 Image-Derived Input Function for (-)-[18F]Flubatine Using a Digital PET System (European Journal of Nuclear Medicine, 2024)

  10. 💊 What Is the Impact of Nicotine on the Post-COVID-19 Syndrome? – A Case Series (Preprint, 2025)

Conclusion:

Dr. Marco Leitzke is a highly deserving candidate for the Best Researcher Award due to his pioneering contributions to understanding and treating Long COVID and neuroimmune disorders. His strong publication record, interdisciplinary approach, and clinical insight mark him as a leading figure in his field. With enhanced international collaboration and clinical validation of his findings, his impact could be even greater. Overall, his research is timely, innovative, and of substantial scientific and societal importance.

Dia Aldeen Alfaki | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. Dia Aldeen Alfaki | Immunology Cellular Interactions | Best Researcher Award

Mr. Dia Aldeen Alfaki , Alzaiem Alazhari University , Sudan

Dia Alfaki is a Sudanese biomedical scientist with a Master of Biomedical Sciences and extensive experience in haematology, molecular biology, and immunology. His research focuses on the complexities of disease mechanisms and therapeutic solutions, particularly within immunology. As a junior researcher and PG Member of the British Society of Immunology, Dia has contributed significantly to studies on malaria and immune responses. His academic background includes a Master’s degree from Alzaiem Alazhari University and a Bachelor’s degree from Omdurman Islamic University. Dia’s dedication to understanding disease complexities through research is reflected in his growing academic presence and expertise in clinical laboratory techniques. He is committed to advancing scientific knowledge and improving healthcare solutions through his research endeavors.

Publication Profile: 

Orcid

Strengths for the Award:

Dia Alfaki has a remarkable blend of educational qualifications, practical experience, and academic research, making him highly suitable for the Research for Best Researcher Award. His work spans critical areas in biomedical sciences, with a special focus on immunology, haematology, and molecular biology, especially in relation to infectious diseases like malaria. His Master’s research on immune responses to Plasmodium falciparum infection stands out, demonstrating his ability to identify novel immunological markers. His published work in well-regarded journals like Microbiologia Medica and Immunology & Cell Biology further showcases his expertise. He has actively contributed to the scientific community through various international conferences, highlighting his commitment to advancing research. His work at G42 Healthcare underscores his technical skills in molecular diagnostics and cutting-edge biomedical research. His collaborative nature, critical thinking, and proven leadership in research make him a strong contender for this award.

Areas for Improvement:

While Dia Alfaki has a solid foundation in immunology and biomedical research, further expansion of his research portfolio into diverse therapeutic fields could enhance his profile. Gaining more experience in clinical settings beyond molecular labs could provide him with a broader perspective in healthcare applications. Additionally, his involvement in multi-disciplinary research collaborations across diverse disease areas such as oncology and genomics would elevate his impact on global biomedical challenges. Developing greater expertise in bioinformatics tools and integrating them into his molecular research would further refine his analytical skills and position him as an even more influential scientist in his field.

Education:

Dia Alfaki holds a Master’s degree in Biomedical Sciences from Alzaiem Alazhari University (2014-2016), where he specialized in Medical Laboratory Sciences with a focus on Haematology and Blood Transfusion, achieving a CGPA of 3.19/4.0. He completed his Bachelor’s degree in Medical Laboratory Sciences from Omdurman Islamic University (2007-2011), where he excelled in Hematology and Immunohematology. Additionally, Dia is pursuing certification as an International Medical Lab Technologist in Hematology (ASCPi) from the American Society for Clinical Pathology (2022-2025). His academic and professional development demonstrates a strong foundation in biomedical sciences, preparing him to make significant contributions to immunology research and clinical diagnostics.

Experience:

Dia Alfaki has worked as a Molecular Lab Technologist at G42 Healthcare (Biogenix Molecular Labs) from 2020-2023, contributing to advanced molecular research and diagnostics. His expertise spans a wide range of laboratory techniques, particularly in immunology, molecular biology, and hematology. Throughout his career, Dia has been involved in various research projects, including his Master’s thesis focused on the immune response to Plasmodium falciparum infection. He has also contributed to several high-impact publications, collaborating with experts in the field of malaria, immune phagocytosis, and cancer immunology. His role in molecular diagnostics has allowed him to apply his research findings to real-world clinical settings, furthering the understanding of disease pathology and therapeutic interventions.

Awards and Honors:

Dia Alfaki has been recognized for his significant contributions to biomedical science, particularly in immunology research. He participated in prominent international conferences, including the 6th European Congress of Immunology (2022) and the American Association for Cancer Research Annual Meeting (2021). His ongoing work in malaria immunology and cancer immunology is highly regarded in scientific communities. As a PG Member of the British Society of Immunology since 2021, Dia continues to gain recognition for his research on immune responses and inflammation. His work has also been highlighted in various prestigious journals, where his research on malaria and immune responses has earned accolades. These honors reflect his commitment to advancing scientific knowledge and improving healthcare through rigorous research.

Research Focus:

Dia Alfaki’s research is primarily focused on immunity, inflammation, cancer immunology, and molecular oncology. His work emphasizes understanding disease mechanisms, particularly the immune responses involved in infections like malaria and the pathogenesis of diseases such as cancer. Dia is particularly interested in the role of immune mediators, phagocytosis, and molecular interactions in disease progression and therapy. His research aims to explore therapeutic perspectives in immunology, using molecular and cellular approaches to better understand disease complexities and improve treatment options. His publications highlight these areas, especially in the context of malaria and inflammatory immune responses. Dia is also committed to utilizing molecular techniques and bioinformatics tools to contribute to new therapeutic strategies for immunological diseases.

Publications Top Notes:

  1. Patterns of Mannose-Binding Lectin (MBL) responses to Plasmodium falciparum infections in hyperendemic settings 📚🔬
  2. Inflammatory immune mediators and Plasmodium falciparum infection: a cross-sectional study among Sudanese patients with severe and uncomplicated malaria 🌍🦠
  3. Monocytes to lymphocytes ratio in peripheral blood and immunoglobulin IgE levels as indicators to Plasmodium falciparum infection in Sudan 📖🔬
  4. The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy 🦠🔬
  5. Plasmodium falciparum and immune phagocytosis: characterization of the process 🦠💉

Conclusion:

Dia Alfaki is an outstanding researcher with a well-rounded background in biomedical sciences, molecular biology, and immunology. His research accomplishments, publications, and contributions to international conferences highlight his drive for advancing scientific knowledge, particularly in the area of disease mechanisms and immune responses. His strong academic foundation, coupled with his practical lab experience and active engagement with the scientific community, positions him as an excellent candidate for the Research for Best Researcher Award. With a few areas of growth in clinical practice and cross-disciplinary collaborations, he has the potential to become a leader in global biomedical research.

Mehmet Ali Karaselek | Immunology | Best Researcher Award

Published on by Cell Biologist

Dr. Mehmet Ali Karaselek | Immunology | Best Researcher Award

Dr. Mehmet Ali Karaselek , Necmettin Erbakan Üniversitesi , Turkey

Dr. Mehmet Ali Karaselek is an accomplished immunologist, widely known for his work on genetic immunodeficiencies and immune system disorders. He holds a significant position in clinical immunology, focusing on T-cell subsets, immune profiling, and the molecular mechanisms behind various immune diseases. His expertise extends to autoimmune diseases, cancers, and rare immunodeficiencies such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency. His extensive research has contributed to a deeper understanding of immune system dysfunctions and therapeutic implications, especially in immune deficiency conditions. Dr. Karaselek is also involved in training future scientists and physicians, combining his expertise in molecular immunology with clinical practice to improve diagnostic and therapeutic approaches in immunology. His publications and ongoing research projects continue to enrich the field of clinical immunology and immunogenetics.

Publication Profile:

Orcid

Strengths for the Award:

  1. Expertise in Immunology: Dr. Karaselek has contributed significantly to understanding immune system disorders, particularly immune deficiencies and their relationship with genetic mutations. This is reflected in several of his articles related to immune cell subsets, immune disorders like immunodeficiencies (e.g., CD19 deficiency, DCLRE1C deficiency), and T-cell and NK-cell functions.

  2. Innovative Research Areas: His focus on transcription factor and cytokine expression in various T-cell subsets, as well as his recent work in cancer-related therapies using pillar[5]arene derivatives, illustrates a strong grasp of cutting-edge topics in both immunology and drug development.

  3. Collaboration Across Fields: Dr. Karaselek’s research spans multiple fields, including cancer research, immunodeficiencies, and genetic disorders, showcasing his ability to work across disciplines. He has collaborated with many researchers on complex issues like genetic mutations and immune dysfunctions, highlighting his team-based approach and leadership in the research community.

  4. Contributions to Clinical Immunology: His numerous articles in high-impact journals, such as the Journal of Clinical Immunology, Expert Review of Clinical Immunology, and APMIS, demonstrate his dedication to advancing clinical research, improving diagnostics, and understanding immune system pathologies.

  5. High Publication Frequency: The volume of publications and the consistency of research output in recent years (2023–2025) reflects a high level of productivity and dedication to his field. This output signifies Dr. Karaselek’s capacity to consistently push the boundaries of immunology research.

Areas for Improvement:

  1. Broader Global Recognition: While Dr. Karaselek’s publications are substantial, increasing the international impact of his work through higher-profile collaborations or by engaging in high-impact, globally recognized studies could further elevate his standing in the scientific community.

  2. Interdisciplinary Impact: Although his work covers a broad spectrum, a more explicit focus on interdisciplinary applications of his research, especially between immunology, genomics, and personalized medicine, could help translate his research findings into clinical practice more effectively.

  3. Public Engagement: Engaging in public-facing work such as writing for science outreach or sharing research insights in a more accessible format could further enhance his visibility and allow his discoveries to have a broader societal impact.

Education:

Dr. Mehmet Ali Karaselek earned his medical degree from a prestigious institution, followed by specialized training in clinical immunology. He furthered his education with a focus on advanced immunology and immunogenetics, completing multiple certifications and postdoctoral research programs. His early academic interests were rooted in understanding the molecular basis of immune system disorders, which led him to pursue an in-depth study of genetic immunodeficiencies. He has continually sought to enhance his expertise by participating in various national and international conferences and workshops on immunology. Throughout his career, Dr. Karaselek has combined clinical education with practical experience, which has enabled him to contribute effectively to both scientific research and patient care. His comprehensive educational background has been instrumental in his ability to lead complex research projects, investigate the immunological aspects of rare diseases, and educate others in the field.

Experience:

Dr. Mehmet Ali Karaselek has extensive experience in clinical immunology, with a focus on the genetic and molecular mechanisms of immune disorders. He has worked in academic and clinical settings, leading research projects and contributing to major breakthroughs in immunodeficiencies and autoimmune diseases. Over the years, he has collaborated with a wide range of medical professionals, contributing to the diagnosis and treatment of rare genetic conditions such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency. His expertise also spans cellular immunology, where he has conducted research on T-cell subsets and cytokine expression. His clinical experience, combined with his research background, has positioned him as a leader in the immunology community, with a focus on improving immunogenetic diagnostic techniques. Dr. Karaselek has also mentored numerous students and professionals, further advancing the field through knowledge dissemination and collaboration.

Research Focus:

Dr. Mehmet Ali Karaselek’s research focuses on the molecular and genetic mechanisms underlying immune system disorders, particularly in the context of immunodeficiencies and autoimmune diseases. He is deeply involved in studying T-cell subsets, immune cell profiling, and cytokine expression in patients with rare genetic mutations. His work has shed light on the pathophysiology of conditions such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency, with the aim of improving diagnosis and treatment options. Dr. Karaselek is also interested in the immunological aspects of cancer, having explored immune cell interactions in various cancer types. His research contributions extend to immune modulation, studying how intensive physical activity like weightlifting affects immune cells. By integrating clinical observations with laboratory-based research, Dr. Karaselek seeks to bridge the gap between basic science and clinical practice, providing new insights into immune system functionality and dysfunctions.

Publications Top Notes:

  1. Investigation of Transcription Factor and Cytokine Gene Expression Levels in Helper T Cell Subsets Among Turkish Patients Diagnosed with ICF2 and ICF3 Syndrome 🧬🧪
  2. Association of NK cell subsets and cytotoxicity with FCGR3A gene polymorphism in functional NK cell deficiency 🧫🔬
  3. Changes in T-cell subsets occur in interstitial lung disease and may contribute to pathology via complicated immune cascade 🫁🩸
  4. Effect of intensive training on immune system cells in elite female weightlifters 🏋️‍♀️🦠
  5. Evaluation of transcription factors and cytokine expressions of T-cell subsets in CD19 deficiency and their possible relationship with autoimmune disease 🤧🔬
  6. Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation 🧬🔬
  7. Variable clinical presentation of hypomorphic DCLRE1C deficiency from childhood to adulthood 👶👨‍⚕️
  8. Water-soluble Pillar[5]arene-based drug candidates for lung and breast cancer 🧪🌊
  9. Could immune cells be associated with nephropathy in Fabry disease patients? 💉🩺
  10. Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines 🧬💊

Conclusion:

Dr. Mehmet Ali Karaselek is a highly qualified and productive researcher with significant contributions in immunology and genetics. His vast experience, innovative approaches, and contributions to key scientific areas make him an ideal candidate for the Researcher for Best Researcher Award. Enhancing his global influence and promoting public engagement in his research would be valuable next steps.

Isabelle Brigaud | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mrs. Isabelle Brigaud | Immunology Cellular Interactions | Best Researcher Award

Mrs. Isabelle Brigaud , CNRS IS2M , France

Isabelle Brigaud is an experienced research engineer at CNRS IS2M, Mulhouse, France. With a strong foundation in molecular biology, biochemistry, cell biology, and bioinformatics, she specializes in the study of biomaterials, tissue engineering, and immunology. Brigaud has made significant contributions to understanding the foreign body response to materials such as silicone breast implants and injectable hydrogels. Her expertise spans molecular cloning, protein analysis, and the development of study models using ex vivo, animal models (e.g., zebrafish, Drosophila, and Spodoptera littoralis), and advanced imaging techniques like confocal microscopy. Passionate about collaborative research, she is involved in managing cross-functional projects, fundraising, and mentoring students. Brigaud holds CNU qualifications in cell biology and physiology and is an advocate for continuous technical training. Her research has resulted in numerous high-impact publications in the field of biomaterials and molecular biology.

Publication Profile:

Orcid

Strengths for the Award:

  1. Diverse and High-Impact Research Focus: Isabelle Brigaud’s research spans multiple biological disciplines, including molecular biology, biochemistry, cell biology, and biophysics, showing a broad and in-depth understanding of biological processes. This is particularly demonstrated through her contributions to studies in immunogenic responses in breast implant tissue, the molecular mechanisms of endometriosis, and cellular interactions with biomaterials, indicating her versatility in tackling diverse biological challenges.
  2. Strong Publication Record: Brigaud has a consistent publication history in high-impact journals, such as Biomaterials, Nature Communications, Acta Biomater, and PRS. These publications focus on important topics like cellular migration, biomaterial interaction, and regenerative medicine, all of which are at the forefront of current biomedical research. Her work on the interaction of biomaterials with tissues, especially focusing on inflammatory responses, positions her as a leading researcher in the field.
  3. Expertise in Advanced Techniques: She is proficient in a wide range of cutting-edge techniques, from molecular biology techniques like RNAseq and PCR to cell biology methods, including cell differentiation and functional pharmacology. This technical expertise is key for producing reliable, reproducible results, which is crucial for advancing scientific knowledge.
  4. Cross-Disciplinary Collaboration: Brigaud’s experience in collaborating across various research teams, institutions, and international boundaries highlights her ability to contribute effectively to multidisciplinary research projects. She has also demonstrated leadership in supervising and training students and researchers, underscoring her role as a mentor and leader in the research community.
  5. Management and Funding Expertise: As a research engineer and project manager, she has led several important projects, such as those related to soft tissue reactions to implants and muscle regeneration. Her experience in fundraising and project management indicates strong organizational and leadership skills, both of which are crucial for steering complex research initiatives toward success.
  6. Commitment to Health-Related Research: Her work on health-related issues, such as the effects of silicone breast implants on immune responses and the management of endometriosis symptoms through exercise, shows a direct impact on improving human health. Her research addresses real-world health challenges, making it highly relevant and applicable to clinical settings.

Areas for Improvement:

  1. Broader Dissemination of Findings: While Brigaud has an impressive publication record, there is a potential for more dissemination of her findings to the broader scientific community, especially through high-visibility conferences and workshops. Increased visibility could attract more collaborative opportunities and funding for her projects.
  2. Expanding Research Focus on Novel Therapeutic Applications: Brigaud’s research has already significantly contributed to understanding biomaterials and cell interactions. Further expansion into therapeutic applications, such as designing and testing novel drug delivery systems or regenerative therapies, could strengthen her profile as a researcher with direct clinical and pharmaceutical applications.
  3. Increased Focus on Large-Scale Collaborative Projects: While Brigaud has demonstrated leadership in individual projects, engaging in larger, multi-institutional collaborative projects could provide even more resources and amplify the impact of her research on a global scale.
  4. Enhancing Outreach to Broader Audiences: Given her expertise in addressing important clinical and biomedical issues, there may be an opportunity for Brigaud to engage with broader non-specialist audiences, including through public science communication platforms, to make her work more accessible to the general public.

Education:

Isabelle Brigaud holds a PhD in Molecular Biology and Insect Physiology from Jussieu, Paris VI, awarded with first-class honors in 2008. She also completed a Master 2 in Integrative Biology and Physiology, specializing in adaptation to the environment, and a Master 1 in Population and Ecosystem Biology and Ecophysiology, both from Jussieu, Paris VI, with honors. Brigaud has expanded her academic credentials with postdoctoral research experiences at the University of Freiburg, Germany (2012-2014), focusing on the cytoskeleton organization in zebrafish development. Prior to that, she conducted research at CNRS/INSERM in Lyon, France (2009-2011), where she studied the plasticity of cell morphology during Drosophila oogenesis. Her academic journey reflects a deep commitment to understanding molecular biology, cell biology, and biochemistry, which has shaped her research trajectory and expertise in biomaterials and tissue engineering.

Experience:

Isabelle Brigaud has extensive experience in molecular biology, cell biology, and biochemistry. She has worked at CNRS IS2M, Mulhouse, France, since 2019 as a research engineer, managing biomolecule platforms and leading studies on the foreign body response to silicone implants and injectable hydrogels. Brigaud previously held postdoctoral research positions at the University of Freiburg, Germany, and CNRS/INSERM, Lyon, France, where she investigated cytoskeletal dynamics in zebrafish lateral line development and cell morphology plasticity during Drosophila oogenesis. During her PhD at INRAE, Versailles, she focused on pheromone detection mechanisms in pest moths, an experience that formed her expertise in molecular biology and insect physiology. In addition to her hands-on research, Brigaud is involved in cross-functional project management, collaborative teamwork, and student supervision, demonstrating strong leadership skills and a passion for advancing scientific knowledge.

Awards and Honors:

Isabelle Brigaud’s work has been recognized through several prestigious publications and her contributions to the fields of biomaterials and molecular biology. Her research on the foreign body response to silicone breast implants and injectable hydrogels has made significant strides in understanding tissue regeneration and inflammatory responses. As an active member of the research community, she has been involved in multiple high-impact journal articles published in prominent scientific journals such as Biomaterials, Acta Biomaterialia, and Nature Communications. Although specific awards are not detailed in her profile, her extensive publication record, including multiple first-author and co-author contributions, highlights her ongoing influence in the scientific community. Brigaud’s commitment to advancing knowledge in biomaterials, molecular biology, and tissue engineering is further demonstrated through her leadership roles in cross-disciplinary projects, mentoring students, and managing research collaborations.

Research Focus:

Isabelle Brigaud’s research focuses on the intersection of molecular biology, biomaterials, and tissue engineering, with a specific interest in understanding the foreign body response to implants and regenerative therapies. Her work explores the immune reactions induced by materials like silicone breast implants and injectable hydrogels, aiming to improve tissue regeneration and reduce inflammation. Brigaud’s expertise includes molecular cloning, protein analysis, cell culture, and advanced imaging techniques, all of which she applies to study cell behavior, tissue interactions, and the effects of materials on cellular processes. She uses animal models, including zebrafish and Drosophila, to investigate cell morphology plasticity and mechanotransduction. Her focus also extends to the development of drug delivery systems and the role of extracellular matrix in inflammation and tissue healing. Brigaud’s collaborative approach to research has led to significant advances in the study of immunology, regenerative medicine, and biomaterials.

Publications Top Notes:

  • Brigaud I et al., 2024. Breast implant silicone exposure induces immunogenic response and autoimmune markers in human periprosthetic tissues. Biomaterials 🔬💉
  • Ouedraogo C et al., 2024. Fabrication and characterization of thin self-rolling film for anti-inflammatory drug delivery. Colloids Surf B Biointerfaces 💊🧬
  • Escriva-Boulley G et al., 2023. Effects of physical activity and endometriosis-based education program delivered by videoconference on endometriosis symptoms: the CRESCENDO program. Trials 🏃‍♀️🩺
  • Brigaud I et al., 2020. Surface texturization of breast implants impacts extracellular matrix and inflammatory gene expression in asymptomatic capsules. PRS 🦠🔬
  • Wakhloo NT et al., 2019. Actomyosin, vimentin and LINC complex pull on osteosarcoma nuclei to deform on micropillar topography. Biomaterials 🦴🔬
  • Pieuchot L et al. 2018. Curvotaxis directs cell migration through cell-scale curvature landscapes. Nature Commun. 🌍🧬
  • Brigaud I et al. 2017. Synergistic effects of BMP-2, BMP-6 or BMP-7 with human plasma fibronectin onto hydroxyapatite coatings: A comparative study. Acta Biomater. 🧫
  • Brigaud I et al., 2015. TGFbeta/activin signaling induces epithelial cell flattening during Drosophila oogenesis. Biol Open 🦗💡
  • Montagné N et al., 2012. Functional characterization of a sex pheromone receptor in the pest moth Spodoptera littoralis by heterologous expression in Drosophila. European Journal of Neuroscience 🦋👃
  • Montagne N et al.,2011. Functional characterization of a sex pheromone receptor in the pest moth Spodoptera littoralis. Chemical Senses 🦋💨
  • Brigaud I et al., 2009. Identification of an atypical insect olfactory receptor subtype highly conserved within noctuids. FEBS Journal 🦗👃
  • Brigaud I et al. 2009. Cloning and expression pattern of a putative octopamine/tyramine receptor in antennae of the noctuid moth Mamestra brassicae. Cell and Tissue Research 🦋🧬

Conclusion:

Isabelle Brigaud is undoubtedly a strong contender for the Research for Best Researcher Award. Her multifaceted expertise, robust publication record, and impactful contributions to molecular biology, cell biology, and biochemistry, particularly in the context of health applications, position her as a leader in her field. With her proven ability to manage large-scale research projects and mentor the next generation of scientists, she continues to make significant strides in biomedical research. By focusing on increasing the visibility of her findings and expanding her research into therapeutic domains, Brigaud could further elevate her already outstanding career.